Wellington Management Group LLP Has $363.79 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Wellington Management Group LLP lowered its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,444,012 shares of the company's stock after selling 69,744 shares during the quarter. Wellington Management Group LLP owned 3.45% of Vaxcyte worth $363,787,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PCVX. Janus Henderson Group PLC boosted its stake in Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. Norges Bank bought a new position in shares of Vaxcyte during the fourth quarter worth about $90,069,000. Vanguard Group Inc. raised its position in Vaxcyte by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after buying an additional 521,204 shares during the last quarter. RA Capital Management L.P. lifted its stake in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after acquiring an additional 485,436 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Vaxcyte during the 3rd quarter worth approximately $41,114,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,250 shares of company stock valued at $3,170,738. Company insiders own 3.10% of the company's stock.

Remove Ads

Vaxcyte Stock Up 3.4 %

Shares of NASDAQ PCVX traded up $1.04 during midday trading on Friday, hitting $31.60. 5,690,652 shares of the company's stock were exchanged, compared to its average volume of 1,119,961. The firm has a market capitalization of $4.07 billion, a PE ratio of -6.87 and a beta of 1.26. Vaxcyte, Inc. has a 12 month low of $29.57 and a 12 month high of $121.06. The company's 50 day moving average price is $74.59 and its 200 day moving average price is $89.47.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of research reports. Guggenheim reissued a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America reduced their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Needham & Company LLC lowered their price target on Vaxcyte from $140.00 to $90.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Vaxcyte currently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.